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Philadelphia negative myeloproliferative neoplasms (MPNs) are clonal hematological 28 
diseases characterized by excessive production of mature blood cells. Exome se-29 
quencing of patient samples have showed a relatively low degree genomic complexi-30 
ty for these diseases1. The majority of MPN patients carry somatic mutations in the 31 
JAK2 gene, with the JAK2V617F missense mutation being the most common in poly-32 
cythemia vera (PV, 95%) and essential thrombocythemia  (ET, 60%) 2. 33 
MicroRNAs (miRNAs) act as post-transcriptional regulators of gene expression, regu-34 
late signaling, and can diffuse from one cell to another through the extracellular 35 
space or the bloodstream. However, although they have been implicated in the path-36 
ophysiology of multiple hematological malignancies, their role in MPNs and the effect 37 
of JAK2V617F mutation on miRNA expression has not been elucidated 3. 38 
Here we used the erythroblastic leukemia cell line HEL, which carries the activating 39 
JAK2V617F mutation, to globally determine differences in miRNA expression after 40 
JAK2 inactivation. We profiled miRNAs expression by Next Generation Sequencing 41 
for microRNAs (miRNA-seq) in HEL cells (Figure 1a and Supplementary Figure S1) 42 
treated for 16 hours with 3µM TG101209, which inhibits JAK2 signaling (Figure 1d). 43 
We detected 143 miRNAs exhibiting statistically significant changes (Benjamini-44 
Hochberg adjusted p ≤ 0.01) in expression after JAK2 inhibition (Supplementary Ta-45 
ble S1).   46 
miR-101 is encoded by two loci, one adjacent to the JAK2 locus; little is known about 47 
its function in myeloid cells 4, so we focused our attention on this miRNA. We validat-48 
ed miR-101 down-regulation by RT-qPCR in HEL cells using two additional JAK2 in-49 
hibitors, TG101348 and AT9283 (Supplementary Figure S1a and S2b). Next, we 50 
compared miR-101 expression level in three hematopoietic cell lines, K562, UKE-1 51 
and HEL, which carry 0, 2 and ≈9 copies of the JAK2V671F allele respectively, and 52 
found that its expression correlates with the extent of the JAK2V617F mutation (Sup-53 
plementary Figure S2c). This result led us to hypothesize that JAK2V617F-positive 54 
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MPN patients exhibit increased miR-101 levels. To test this, we cultured and individ-55 
ually genotyped single cell-derived BFU-E colonies from JAK2V617F–positive ET 56 
and PV patients and pools of 20 colonies were analysed5 (Supplementary Table S2). 57 
We found an increased miR-101 expression in JAK2V617F-positive BFU-e colonies 58 
compared to WT in both ET and PV patients (Figure 1b left panel). Next, we meas-59 
ured miR-101 levels in the serum of 14 JAK2V617F-positive ET and PV patients 60 
(Supplementary Table S2), and observed higher levels of circulating miR-101 in pa-61 
tients compared to controls (Figure 1b right panel, p=0.0072). The level of circulating 62 
miR-101 does not correlate with diagnosis (ET vs PV p=0.32) or JAK2V617F-63 
homozygosity (Supplementary Figure S1c and S1d). These observations suggest 64 
that miR-101 expression is increased by JAK2V617F in ET and PV patients’ erythroid 65 
cells and it is released into the blood stream.  66 
Two different loci encode miR-101 primary transcript (pri-miR-101) in the human ge-67 
nome. While miR-101-1 is intergenic, miR-101-2 is located within the last intron of the 68 
ribosomal protein gene RCL1, immediately upstream of JAK2 (Supplementary Figure 69 
S2d). Both precursors give rise to the same mature miRNA. Thus, we asked whether 70 
miR-101 expression from both loci was equally affected by mutant JAK2, and meas-71 
ured the expression of both primary transcripts by qPCR. Interestingly, we observed 72 
increased pri-miR-101-1 but not pri-miR-101-2 levels after JAK2 inhibition (Figure 73 
1c). Increased primary transcript levels might be the result of a reduced Microproces-74 
sor-mediated pri-miRNA processing upon inhibition of JAK2 activity. Importantly, the 75 
activity of the Microprocessor complex (composed of Drosha and DGCR8) is finely 76 
regulated by the helicases DDX5 (p68) and DDX17 (p72), which interact directly with 77 
Drosha/DGCR8 in vivo and facilitate cleavage of specific subsets of pri-miRNAs 6,7. 78 
Therefore, we measured Drosha, DDX5 and DDX17 protein levels after treating HEL 79 
cells with JAK2 inhibitor TG101209 and found a decrease in DDX5 and DDX17 ex-80 
pression (Figure 1d), not paralleled by a lower mRNA expression for DDX5 or DDX17 81 
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(Supplementary Figure S2e). Thus, we speculate that JAK2 activity might enhance 82 
pri-miR-101-1 processing through increased activity of the Microprocessor by stabiliz-83 
ing DDX5 and DDX17 helicases. The specific effect on pri-miR-101-1 might be due to 84 
the presence of a conserved CNNC motif on its precursor (Supplementary figure S3), 85 
allowing specific enhancement of nuclear processing 8.  86 
Next, we investigated the consequences of increased miR-101 on its predicted target 87 
genes. In silico search resulted in 156 overlapping genes using three algorithms (mi-88 
Randa, Targetscan and PicTar). Gene Ontology (GO) and Kyoto Enciclopedia of 89 
Genes and Genomes (KEGG) pathway analysis of this gene set identified and identi-90 
fied JAK/STAT pathway components as putative miR-101 targets. 91 
Suppressors of cytokine signaling (SOCS) proteins are involved in suppression of 92 
JAK2/STAT5 signaling. Early studies showed partial efficacy of these proteins on 93 
JAK2V617F mediated signaling 9, but recent work suggests SOCS proteins are ca-94 
pable of inhibiting JAK2V617F. Particularly, both SOCS1 and SOCS3 were shown to 95 
inhibit JAK2/STAT5 signalling in HEL cells and their overexpression correlate with 96 
decreased cell proliferation10.   We focused our attention on SOCS2,  negative regu-97 
lator of JAK2 and mutant JAK2V617F11. Despite being rare, loss of function muta-98 
tions of SOCS2 have been described in MPN patients 12. We hypothesized that the 99 
observed miR-101 upregulation might functionally mimic the effect of SOCS2 muta-100 
tion and contribute in maintenance of JAK2V617F constitutive signaling. Using re-101 
porter constructs with either WT or a mutant SOCS2-UTR, we compared the ability of 102 
miR-101 to silence luciferase. We found that miR-101 overexpression significantly 103 
reduced luciferase activity in the presence of WT but not the mutant SOCS2-UTR 104 
(Supplementary Figure S4a and S4b). In addition, overexpression of miR-101 in 105 
K562 cells resulted in a significant reduction in both SOCS2 protein and mRNA levels 106 
(Figure 2a and Supplementary Figure S4c). Other members of the SOCS family were 107 
not affected by miR-101 overexpression (Figure 2a). Moreover, SOCS2 mRNA ex-108 
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pression was reduced in JAK2V617F-mutant relative to WT BFU-E colonies from ET 109 
and PV patients (Figure 2b) 110 
We then tested the consequence of miR-101 inhibition in HEL cells, using a specific 111 
miR-101 Locked Nucleic Acid (LNA) antisense inhibitor. We observed significantly in-112 
creased apoptosis 48 hours after transfection, increased SOCS2 protein (Figure 2c 113 
and 2d) and mRNA levels (Supplementary Figure S4d).  The decrease in STAT5 114 
phosphorylation is mediated by SOCS2 as both SOCS1 and SOCS3 showed no in-115 
crease after miR-101 inhibition (Figure 2d).  116 
Though miR-101 was shown to target the JAK2 UTR 13, JAK2 protein levels were un-117 
changed by miR-101 inhibition in HEL cells (Figure 2d) as well as miR-101 overex-118 
pression in K562 cells (Supplementary Figure S5). This suggests JAK2-3’ UTR might 119 
have a different affinity for miR-101 in different cellular contexts 14. We conclude that 120 
miR-101 repression allows the specific increase of JAK2/STAT5 negative regulator 121 
SOCS2, which in turn inhibits STAT5 phosphorylation leading to increased apoptosis 122 
of JAK2V617F positive HEL cells.  123 
Taken together, our data support the presence of a positive feedback loop whereby 124 
JAK2-V617F constitutive activity allows more efficient pri-miR-101 processing, in-125 
creasing mature miR-101 levels in erythroid cells. In turn, this potentiates repression 126 
on SOCS2 (Supplementary Figure S6). Increased miR-101 as a consequence of 127 
JAK2V617F mutation could further enhance the constitutively active JAK2 signaling 128 
cascade. The high levels of miR-101 observed in patients JAK2V617F-positive 129 
clones suggest that this mechanism could be active in the mutant cells, and the in-130 
creased level of circulating miR-101 might mediate the same effects also in the WT 131 
clone thus potentiating JAK2/STAT5 signaling in these cells.   132 
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Figure Legends 143 
 144 
Figure 1. JAK2V617F alters miRNAs expression a) Heatmap of the miRNAs seq 145 
shows significant change in HEL cells after TG101209 treatment. b) Dot 146 
plots show relative miR-101 expression, in paired WT and mutant V617F 147 
heterozygous BFU-e colonies from ET and PV patients and serum from 148 
healthy controls and JAK2V617F-positive PV and ET patients. c) Bargraph 149 
shows qPCR (averaged ± S.E.M.) quantification of mature miR-101 and 150 
each miR-101 precursor RNA (pri-miR) N=6. d) Western blot analysis of 151 
HEL cells treated with JAK2 inhibitor. 2way-Anova with Bonferroni post-test 152 
with multiple comparisons  or Student t-test were used as appropriate.  153 
*p≤0.05, ** p≤0.01, *** p≤0.001 154 
Figure 2. SOCS2 is targeted by miR-101 and downreguated in MPN JAK2V617F 155 
colonies a) Western blot analysis after miR-101 overexpression. b) Dot plot 156 
shows SOCS2 gene expression in paired WT and mutant V617F 157 
heterozygous BFU-e colonies from ET and PV patients. c) Bargraph shows 158 
percentage of apoptotic cells after LNA anti-miR-101-LNA transfection in 159 
HEL cells N=8 (averaged ± S.E.M.). d) Western blot analysis of HEL cells 160 
after anti-miR-101-LNA treatment. Student t-test was used. *p≤0.05,** 161 
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p≤0.01,*** p≤0.001.   162 
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